MK-6186
MK-6186 is a novel non-nucleoside reverse transcriptase inhibitor with sub-nanomolar activity against wild-type viruses and the two most common NNRTI-resistant RT mutants (K103N and Y181C) . MK-6186 exhibits excellent antiviral activity against K103N and Y181C mutant viruses. When MK-6186 targets 12 common NNRTI-associated mutant viruses, only two relatively rare mutants (Y188L and V106I/Y188L) show high resistance, with FC values exceeding 100, while the FC values of the remaining viruses are all below 10. In addition, when MK-6186 faces 96 clinical virus isolates carrying NNRTI-resistant mutations, most (70%) viruses show more than 10-fold resistance to efavirenz (EFV), while only 29% of mutant viruses show more than 10-fold resistance to MK-6186[1].
Product Specifications
CAS Number
1034474-19-5
UNSPSC
12352005
Target
Endogenous Metabolite
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/mk-6186.html
Smiles
N#CC1=CC(Cl)=CC(OC2=C(C=CC3=C2C=NN3CC4=NNC5=C4C=CC=N5)Cl)=C1
Molecular Formula
C21H12Cl2N6O
Molecular Weight
435.27
References & Citations
[1]Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Galectin 1 (LGALS1) Human Gene Knockout Kit (CRISPR)
Annexin A1 / (Hairy Cell Leukemia Marker) (ANXA1/1672), CF594 conjugate, 0.1mg/mL
